EBOLA: RESEARCHERS FROM CHINA DEVELOP NOVEL EBOLA VACCINE

Researchers in China have developed a novel Ebola vaccine. The phase One trial of the vaccine has been successfully completed on 120 healthy volunteers from Tazhou, Jiangsu province, China.

The vaccine was given in both low and high doses. The high dose was found to be safe and produced immune response within 14 days in participants.

Meanwhile, two experimental vaccines, one developed by NIAID scientists and GlaxoSmithkline and the other developed by Public Health Agency of Canada and licenced to Newlink Genetics Corporation and MERCK which were given to over 600 volunteers in Liberia in the stage two phase is now entering its final testing phase, Stage 3.

Since Liberia transmission rate is currently low, as very few people currently have the virus, it might be difficult to determine how well protected the participants are from the virus.